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Abstract 
Urinary Tract Infections (UTIs) are one of the most common infections in the UK and many 
other parts of the world. The prevalence of the Extended Spectrum β-Lactamases (ESBLs) 
producing UTIs, combined with their ability to form a bio film, has significantly risen and is 
limiting therapeutic options. This study investigated the anti-bio film activity of Manuka honey 
on two ESBL producing pathogens, Escherichia coli TEM-3 and Klebsiella pneumonia SHV18, 
commonly found in UTIs. The ESBL production was confirmed by the double disk synergy 
method used to confirm the ESBL production. The antibacterial activity of Manuka honey was 
determined using the agar well diffusion method. The Minimum Inhibitory Concentration (MIC) 
was established using serially diluted honey ranging from 50% to 1.56%.  The effect of Manuka 
honey on the pathogen bio films was analysed using the Tissue Culture Plate method, with an 
established MIC and under 24h incubation with the honey. The results indicated that K. 
pneumonia SHV18 is a stronger bio film producer than E. coli TEM 3. 50% (w/v) MIC Manuka 
honey appears to fully prevent the plank tonic growth of both strains. A significant reduction of 
81% of the E. coli TEM3 (p < 0.001) and 52% of the K. pneumonia SHV18 (p = 0.001) bio film 
biomass was observed. The E. coli bio films were found to be more sensitive to the 50% (w/v) 
honey dilution than those produced by K. pneumonia. The study indicated the anti-bio film 
potency of Manuka honey and its potential to become an alternative treatment for the ESBL 
producing pathogens associated with UTIs.  
Keywords: Bio films, Manuka honey, ESBLs, biomass, Urinary Tract Infections 
Introduction 
Prevalence of Urinary Tract Infections 
Urinary Tract Infections (UTIs) are among the most common bacterial infections in humans and 
are rapidly increasing in different parts of the world, adding high medical costs to the healthcare 
community (Pitout, 2012 and Patwardhan et al., 2017). UTIs affect approximately 150 million 
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people annually worldwide, and thus have become one of the most common human infections 
(Dash et al., 2018). UTIs are a substantial cause of morbidity, especially in females, elderly men 
and infants (Foxman, 2003). The complications of UTIs can be serious, involving recurrent 
infections, pyelonephritis with sepsis, pre-term birth and renal damage in children. (Reid, 2018). 
The most common bacterial species isolated from UTIs are Escherichia coli, Klebsiella 
pneumonia, Pseudomonas aeruginosa and Proteus mirabilis. More than 80% of UTIs are caused 
by uropathogenic E. coli strains (Trautner et al., 2003). UTIs caused by K. pneumonia were 
considered to be hospital-acquired, due to its ability to attach to plastic medical instruments such 
as urethral catheters (Anes et al., 2017), but they was later found in outpatients spread around the 
community (Mazzariol, 2017).  
Antibiotic resistance and biofilm formation ability of UTI pathogens 
In the early 1960s, two of the clinically important plasmid mediated Beta Lactamase enzymes, 
encoded by the TEM and SHV genes, were identified within E. coli and K. pneumonia, 
respectively (Shaikh et al., 2015). Those strains quickly became resistant to 3rd generation 
antibiotics and became widely known as Extended Spectrum Beta Lactamases (ESBL) 
(Mazzariol, 2017). Clinically, the most important class of ESBLs include the TEM, SHV and 
CTX-M (ur Rahman et al., 2018 and Reid, 2018). A cross-sectional hospital based study on the 
prevelence of resistance among UTIs, carried out in Leicestershire in the UK by the author’s 
research team found that 76% of CTX-M, 3.8% of TEM and 3.8% of SHV account for the UTI 
isolates tested. (Reid et al., 2018). ESBLs produce betalactamase and carbapenemase enzymes, 
which easily hydrolyse the Beta-Lactam ring commonly shared by many antibiotics, such as 
penicillin, carbapenems, cephalosporin’s and aztreonams, used in UTI treatments (Baho et al., 
2018). In recent years many have reported that the rapid dissemination of these ESBL producers 
among UTIs is due to the pathogens’ increased ability to form bio film structures (Patwardhan et 
al., 2017). Hence it is vital to understand the ability of bio film formation of ESBL producing E. 
coli and K. pneumonia to develop an effective treatment for UTIs caused by these pathogens. 
Bacterial bio films are organized bacterial communities embedded in an exopolysaccharide 
matrix on biotic and abiotic surfaces, and are a major problem as they interfere in bacterial 
eradication with antibiotics (Dufour et al., 2010). Bio film formation is a five-step process, as 
illustrated in Figure 1.   Biofilm-associated cells are physiologically and phenotypic ally different 
from free living cells in terms of the cell densities, nutrients, oxygen supply, waste product 
concentration, and gene expression. The increased resistance to antimicrobials is an important 
characteristic of these bio film associated cells, which can reach up to 1000-fold more free living 
cells. This resistance can be implemented through several mechanisms; resistance gene exchange 
within the community, efflux pump expression, modifying pH values and metal ion 
concentration that leads to inactivation of the antibiotic, restriction of the antibiotic diffusion 
through the matrix, and furthermore, the presence of  metabolically inactive persister cells that 
have a high tolerance to antibiotics (Prigent-Combaret et al., 1999, Parsek and Greenberg, 2005, 
Xu et al., 1998, Mikkelsen et al., 2007, Stewart and Costerton, 2001, Lewis et al., 2001). Hence 
collectively, bio film formation represents a significant threat to infection treatment and for many 
antimicrobial treatments fail, as nearly 65-80% of all infections are presumably related to the bio 
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film formation ability of pathogens associated with UTIs (Hall-Stoodley et al., 2004, Costerton et 
al., 1999, Parsek and Singh, 2003). 
Demand for alternative methods for UTI treatment. 
As indicated above, the development of bio films in ESBL producing pathogens among UTIs is 
an issue that needs attention and alternative methods for treatment need to be sought urgently.  In 
the last few years, studies have shown the potential of plant based anti-microbials on Gram-
negative pathogens, and the potential to lower the risk of resistance development, as many of 
these plant based products do not affect the growth and fitness of the pathogens, and hence do 
not exert an associated selection pressure for the tested pathogens (Ravichandiran et al., 2013 
and Tay & Yew, 2013). Of the plant-based products analysed, Manuka honey has demonstrated 
antimicrobial activity against both Gram-positive and Gram-negative bacteria (Bouacha et al., 
2013). Specifically for Gram- negative bacteria, Manuka honey has demonstrated its 
antimicrobial activity in targeting the bacterial outer membrane proteins, leading to instability 
and disruption of the membrane, followed by the cell lysis (Camlin and Maddocks, 2014). The 
antimicrobial activity of Manuka honey is attributed to several factors, including its high 
concentration of sugar and acidity, and the presence of non-peroxide components, such as 
methylglyoxal (MGO), which have been widely explored in many studies (Carter et al., 2016). 
The high level of MGO in Manuka honey is due to the conversion of the dihydroxyacetone 
(DHA) present in the nectar of Leptospermum flowers and is considered the main reason for its 
non-peroxide activity (Kwakman and Zaat, 2012). Manuka honey has played a significant role in 
wound treatment and healing for many years, and, very recently, it was officially approved as an 
alternative antimicrobial for clinical use (Morroni et al., 2018).  
 Although studies have showed the antimicrobial activity on many Gram-negative pathogens, its 
anti-bio film efficacy is not well documented, specifically for Gram-negatives such as ESBL 
producing pathogens. Therefore, the objective of the present study was to analyse the anti-bio 
film efficacy of Manuka Honey on E. coli (TEM-3) and K. Pneumonia (SHV-18), which are 
associated with UTIs. Firstly, the study evaluated the direct antimicrobial activity of Manuka 
honey on the selected strains. Secondly, it evaluated the bio film forming ability of the two 
strains and thirdly, it analysed the effect of Manuka honey on bio film reduction in E. coli (TEM-
3) and K. Pneumonia (SHV-18).  
Materials and Methods 
Bacterial Strains and genotypic detection. 
All of the test and control strains were obtained from the Public Health England, UK, National 
Collection of Type Cultures: NCTC 13351(E. coli TEM-3), NCTC 13368 (K. Pneumonia SHV-
18) and NCTC 12241 (E. coli) and NCTC 9633 (K. pneumonia) were used as controls two 
antibiotics resistant ESBL bacteria strains. The genotypic identification of the ESBL producing 
genes TEM-3 and SHV-18 was confirmed by the multiplex PCR method, as outlined in our 
previous work (Reid et al., 2018). 
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Phenotypic detection of ESBL  
A Double disk synergy test was performed to confirm the ESBL production of the test strains 
according to the MAST ESBL ID double disk synergy method, specified in the 
manufacturer’s instructions (MAST, 2018). Three sets D62C, D52C and D64A were used to 
identify the ESBL strains. Semi- confluent growth cultures were prepared from an overnight 
culture according to the British Society of Antimicrobial Chemotherapy (BSAC) standards 
(BASC, 2013). The discs contained Cefotaxime, Ceftazidime and Cefpodoxime with an ESBL 
inhibitor Clavulanic acid. The plates were incubated at 37°C for 18 hours. A zone of 
inhibition difference of ≥ 5mm between the ESBL producer and the inhibitor indicated a 
positive result in terms of ESBL production.  
 
Manuka Honey sample 
Unpasteurized and cold press Steen’s Manuka Honey UMF 24+ produced in New Zealand 
(Steenshoney.com, 2019) was chosen as a sample. UMF24+ is regarded as having a minimum 
of 1122 mg/kg of Methylglyoxal, which is the key antimicrobial component of Manuka honey 
tested. 
Antimicrobial activity of Manuka honey by Agar Well diffusion 
An Agar Well diffusion assay was performed to determine the antimicrobial effect of the 
honey, based on the protocol described by Boorn et al. (2010), with modifications: Three 8mm 
wells were cut into each agar plate using a sterile cork borer. 150-200µl of 50% (w/v) Manuka 
honey was added to fill each well. The honey dilution was prepared prior to the experiment by 
mixing 2g of Manuka honey with 2ml of sterile water. Dilution of the neat honey was needed 
as the honey was considered dense and adjusted according to the test. Bacterial strains grown 
on nutrient broth were streaked onto Mueller-Hinton Agar (MHA) and incubated with 
Manuka honey at 37°C for 18 hours. After incubation the diameters of the inhibition zones 
were measured. 
 
Minimum Inhibitory Concentration (MIC) 
In order to determine the concentration of Manuka honey to use in the Bio film assays, the 
MIC for both test strains (TEM3 and SHV18) was established, as described previously 
(Sherlock et al., 2010) using sterile 96-well microtiter plates. A starting concentration of 50% 
(w/v) Manuka honey was prepared. Serial dilutions in duplicate of the following 
concentrations, 25%, 12.50%, 6.25%, 3.13%, 1.56%. were created in an LB medium. An 
overnight cultures of test strains were diluted 0.5 McFarland standard in an LB medium and 
200µl of this diluted culture was added to each concentration. The plates were incubated at 
37°C for 18 hours and the shaking incubator at 1000rpm. A positive control, consisting of an 
LB medium and Test strain, and a negative control, consisting of an LB medium only, were 
included in each assay. The MIC was determined as the lowest concentration with no visible 
growth using a spectroscopic assay, as described previously (Patton et al., 2006). The optical 
density (OD600) of the wells was measured using the plate reader SPECTRA max Plus at 
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600nm, prior to incubation (T0) and after incubation (T24). The recorded measurements were 
subtracted (T24- T0) for each of the replicates to see the bacterial growth. To calculate the 
percentage of inhibition in each well, the equation % of inhibition = 1 - (OD test well/OD of 
corresponding control) x 100 was used. Maximal Bacterial Growth (MBG) was performed to 
confirm the MIC of the honey, by spreading 20µl of the suspension from the wells with no 
turbidity present. The MIC was reported as lower honey concentration resulted in 100% of 
inhibition and no MBG. 
 
Detection of bio film formation 
The bio film formed by each test strain was assessed by a Tissue Culture Plate (TCP) assay, as 
described previously (Baho et al., 2018), with modifications: the overnight cultures of the test 
strains were diluted in LB to the ratio of 1:100 to achieve the confluence of 105 cells. 3ml of 
each test strain and the LB medium only, were cultured in triplicate in two separate plates. The 
plates were then incubated at 37°C in a static incubator for 24h. After incubation the cultures 
were discarded carefully and the wells were washed with saline water to remove unattached cells 
to eliminate the background staining. Each well was fixed with 4ml of 99% methanol for 15min; 
then the plates were emptied and left to dry at room temperature for 30 min in an inverted 
position.  After that each was further stained with 4ml of 2% crystal violet for 10min. The stain 
was rinsed with sterile water until clean and the dye was re-solubilised with 4ml of 33% glacial 
acetic acid. After 30min of incubation at room temperature, the optical density of each well was 
measured using spectrophotometer (HλLIOS) at 570nm to evaluate the amount of bio film 
formation. 
Effect of Manuka honey on formed bio films 
To determine the effect of Manuka honey on established bio films (growth under 24 hours in a 
total volume of 2ml in TCP plates) they were treated with MIC of Manuka honey previously 
established for planktonic bacteria. Diluted (1:100) bacterial cultures in a volume of 2ml were 
inoculated in sixapulate together with and LB medium only as a negative control in triplicate in a 
volume of 2ml. After incubation the bacterial cells were discarded and the wells were washed 
with saline water as described previously (Cooper et al, 2011). After that, three wells containing 
the bacterial culture were filled with 2ml of 50% Manuka honey and the next three with 2ml LB 
medium only. The negative control wells were re-filled with 2 ml of LB medium only. The plates 
were then incubated for a further 24 hours. The bio film formation was determined as described 
previously. The average optical density values of the bio films treated with Manuka honey were 
compared with the untreated ones to determine the reduction in bio film biomass after 24 hours 
of Manuka honey treatment. 
Statistical analysis 
Each experiment was performed twice for each test organism and the representative values were 
the average of the triplicates. The data collected were approximately normally distributed. An 
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Independent T test was run to analyse the statistical difference between the control and treated 
groups in SPSS. A P-value <0.05 indicated statistical significance in the reduction of the bio film 
biomass. 
.Results 
ESBL detection and Agar well diffusion. 
The presence of ESBL activity was confirmed by the Double Disk Synergy method for the test 
strains, E. coli TEM-3 and K. pneumonia SHV-18. Both strains showed sensitivity to 
Cefotaxime and Ceftazidime combined with Clavulanic acid (Figure 2). The size of the zone of 
inhibition was measured in millimetre units, recorded on a table and interpreted using MAST 
standard instructions, as shown in Table 1. The agar well diffusion assay demonstrated 
antimicrobial activity of 50% (w/v) Manuka honey for both the test and control strains. However, 
the inhibition of the growth was significantly lower for the ESBL producing strains compared to 
the controls.  Furthermore, we observed that K. pneumonia SHV-18 is more sensitive to honey 
compared to E. coli TEM-3. The inhibition of the growth by Manuka honey for all of the strains 
was represented as an average zone of inhibition, as shown in Table 2.  
MIC of Manuka honey for E. coli TEM-3 and K. pneumonia SHV-18. 
The MIC of Manuka honey for both test strains, E. coli TEM-3 and K. pneumonia SHV-18 was 
observed as the 50% (w/v) honey dilution based on the calculation established by Patton et al. 
(2006), and the results are indicated in Table 3. A massive drop in the inhibition ability of 
Manuka honey was observed for K. pneumonia SHV-18 - below 25% (w/v), whereas for E. coli 
TEM-3, a gradual decrease in inhibition was observed in lower honey concentrations. The 
negative values of inhibition indicated the growth of bacteria. Hence in low Manuka 
concentrations there was increased growth of K. pneumonia SHV-18 growth compared to E. coli 
TEM-3. These results were further confirmed by the Maximal Bacterial Growth (MBG) assay for 
the bacterial cultures treated with 50% (w/v) and 25% (w/v) Manuka honey. MBG has shown 
that the 50% (w/v) honey as the MIC for both ESBL producing strains, as there was no bacterial 
growth on the plates observed. The bacterial cultures consisting of a 25% dilution of honey 
exhibited small growth for E. coli TEM-3, and for K. pneumonia SHV-18 normal growth was 
observed.  
Bio film formation of the E. coli TEM-3 and K. pneumonia SHV-18. 
The ESBL strains were assessed for their bio film-forming ability prior to the Manuka honey 
treatment. The tested strains were classified according to their OD570 values regarding their 
adherence capacity, as mentioned in Baho et al. (2018). An OD570 of less than 0.2 was 
considered as weakly adherent, 0.2-0.4 was considered as moderately adherent, while greater 
than 0.4 was considered as strongly adherent (Table 4). Both strains were identified as having the 
ability to attach and form bio films on a plastic surface in-vitro. The mean amount of bio film 
formed in static conditions by E. coli TEM 3, expressed by the OD570 reading was 0.430, 
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whereas by K. pneumonia SHV18 the OD570 reading was 0.548, which indicates strong 
adherence ability. K. pneumonia produced almost 20% more biomass than E. coli, indicating its 
stronger bio film formation ability. 
The Effect of Manuka honey on E. coli TEM-3 and K. pneumonia SHV-18 bio films. 
 To analyse the efficacy of Manuka honey on E. coli TEM-3 and K. pneumonia SHV-18 bio 
films (grown under 24 h condition), strains were treated with 50% (w/v) Manuka honey and 
incubated for further 24 h period. For the E. coli TEM-3 samples, which were not treated with 
Manuka honey, an OD570 of 0.453 was observed, and for the Manuka honey treated samples, an 
OD570 of 0.084 was observed, indicating an 81% reduction in OD570 in the presence of 
Manuka honey (Figure 3). The mean OD570 for K. pneumonia SHV18 was 0.544, whereas for 
the treated groups it was 0.26, indicating a 52% reduction in OD570 when treated with Manuka 
honey (Figure 4). The results show that both strains are sensitive to Manuka honey treatment 
after 24 hours’ incubation; however E. coli TEM-3 displayed a very sensitive profile, as only 
19% of the bio film biomass remained after treatment. The significant reduction in the bio film 
was confirmed by an Independent T test, as the p value of TEM-3 was reported to be lower than 
0.001 (t value = 119.529; df = 2.048) and the P value of SHV18 was found to be equal to 0.001 (t 
value = 8.261; df = 4). 
Discussion 
Bio film development is a field of intense research for many pathogenic microorganisms, 
associated with bio film infections. However, very few studies have investigated the inhibitors of 
bio film associated ESBL producing UTI pathogens. Therefore, the present study evaluated the 
bio film inhibition activity of Manuka honey on the ESBL producing pathogens, E. coli TEM-3 
and K. pneumonia SHV18, which are commonly associated with UTIs. Our study found that 
Manuka honey exhibited substantial activity in terms of eradicating the biomass of the bio films 
formed by both of the ESBL strains tested. This behaviour may be accounted for by the 
inhibition and annihilation ability of Manuka honey against the bio film-formation process, as 
previously reported in regard to medically important antibiotic resistant Gram-negative strains 
(Emineke et al., 2017 and Okhiria et al., 2009). A greater reduction in the biomass of E. coli 
TEM-3 was observed compared to K. pneumonia SHV-18. Our observation of the ability of low 
inhibition of bio films by Manuka honey on K. pneumonia SHV-18, could be attributed to its 
higher bio film formation ability. This characteristic of K. pneumonia could account for its faster 
kinetics in the bio film formation process; thus it has recently been reported as a strong bio film 
forming pathogen (Surgers et al., 2019). The observed behaviour on greater inhibition by 
Manuka honey on E. coli TEM-3, similarly agreed with other ESBL producing E. coli pathogens, 
as reported previously (Idris and Afegbua, 2017). 
The study undertaken on E. coli by Neupane et al. (2016) highlighted that ESBL producing 
strains have a greater capacity to form bio films, which was further confirmed in our previous 
studies, in relation to the bio film formation ability of non ESBL and ESBL producing pathogens 
(Baho et al., 2018). Similarly, in this study, we have shown that ESBL producing E. coli TEM-3 
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and K. pneumonia SHV-18 also have a strong adherence capacity to form bio films. Hence the 
increased ability of these cells to produce bio films may correlate with the increased resistance to 
many antimicrobials and prevalence in many bio film associated infections, including the 
prevalence of E. coli TEM-3 and K. pneumonia SHV-18 in UTIs. As the above findings and our 
present study, emphasize the correlation between higher bio film production and increased 
antibiotic resistance, it is necessary to find alternative methods or treatments to disturb the bio 
films produced by ESBL producing pathogens.  
The agar well assay was performed in this study to determine the bactericidal activity of Manuka 
honey indicated that the honey has a lower capacity of inhibition against ESBL producing, drug 
resistant strains compared to non – ESBL antibiotic susceptible controls (Table 2). This reduced 
effect of the honey was similarly observed in a previous study on multi-drug resistant, bio film 
associated pathogens (Kwakman and Zaat, 2012).The spectroscopic analysis to determine the 
efficacy of Manuka honey, on tested ESBL strains, indicated that K. pneumonia SHV18 is more 
sensitive to Manuka honey than E. coli TEM-3, as lower concentrations of honey was able to 
inhibit any visual growth of the K. pneumonia SHV18 strain (Table 3). The TCP method was 
chosen for this study as this method has been used as a standard to detect the efficacy of Manuka 
honey, and the method is also the most appropriate in estimating bacterial growth in lower 
concentrations, as reported previously. For example, the highest bacteriogenic activity on ESBL-
producing K. pneumonia was observed at a lower concentration of 30-40% (w/v) in a study by 
Shah Pratibha J, Williamson TM  (2015), and similarly a lower concentration of 30% (w/v) was 
noted in a study on metallo-β- lactamases (NDM-1), ESBL (Qamar et al., 2018). However, 
instead of using serial dilutions, a series of dilutions would allow more precise values in a wider 
range of concentrations, which would improve our current bio film efficacy analysis further. 
In the present study, we observed the biomass reduction of the bio films for both E. coli TEM-3 
and K. pneumonia SHV18, thereby showing the potential anti-bio film efficacy of Manuka 
honey on ESBL producing UTI pathogens. Understanding the mechanism of the honey in bio 
films infections is important, as there is little research available on mechanism of action of 
Manuka honey on E. coli and K. pneumonia bio film associated UTIs.  It was reported that 
Gram- negative being targeted by honey in two different anti-bio film mechanism patterns 
(Camplin and Maddocks, 2014). The first mechanism was attributed to honey’s direct biocidal 
activity, and the second one was attributed to honey’s anti-virulent activity (Camplin and 
Maddocks, 2014). A previous study on the effect of Manuka honey on the Gram-negatives, E. 
coli, and P. merabilis, reported a 15% to 70% biomass reduction due to impaired adhesion within 
these cells (Emineke et al. 2017). Similarly, the biocidal activity of Manuka honey (a reduction 
of bio film biomass up to 85%) due to impaired adhesion was also observed in P. aeruginosa bio 
films when exposed to a 40 % (w/v) Manuka honey concentration (Okhiria et al., 2009).  
Understanding the potency of Manuka honey is also important in these types of  bio film 
analysis, as the potency of honey can vary as much as 100-fold and many studies have reported 
that honey concentrations by (w/v) or (v/v) do not represent the true density of the honey 
considered (Halstead et al., 2016). The degree of dilution is crucial for retaining the 
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antimicrobial activity and this varies between honeys with peroxide and non-peroxide properties 
(Olaitan et al., 2007). Literature argued that which component of Manuka honey is a major 
antagonist of developing bio films as it is necessary to determine how this component in Manuka 
honey interferes with bio film integrity. One possible suggestion regardless of the fact that the 
non-peroxide concentration may vary between Manuka honey brands and further dilution can 
affect its activity, is the ability of Manuka honey to create a high osmotic pressure, which could 
lead to destroying the extracellular matrix of bio films, allowing the active components of the 
honey to penetrate and interact with bacteria on the molecular level. 
Conclusion 
The main results of the present work demonstrate the anti- bio film efficacy of Manuka honey on 
the ESBL producing strains E. coli TEM-3 and K. pneumonia SHV18 and that Manuka honeys 
has the potential to be an effective bio film inhibitor for both strains. The ability to develop bio 
films was confirmed in both E. coli TEM-3 and K. pneumonia SHV18. Furthermore, the bio 
films established by E. coli TEM-3 were found to be more sensitive to Manuka honey activity 
compared to those established by K. pneumonia SHV18, as a greater biomass reduction was 
observed for the E. coli TEM-3. Collectively the results obtained indicate that Manuka honey 
may be a promising antibacterial for the treatment and modulation caused by ESBL pathogens, 
specifically the ESBL producers associated with UTIs. Unlike conventional antibiotics, Manuka 
honey has an extra advantage, as it appears to act on multiple bacterial targets, and hence it has 
the lowest propensity for inducing further resistance among ESBL associated UTI pathogens. 
However, the time and dose dependent manner of biomass reduction need to be further tested, 
specifically the response of the biofilms to different concentrations of Manuka honey over time; 
both shorter and prolonged incubation with Manuka honey need be further analysed. 
Furthermore, the inhibitory effect and influence on bacterial adhesion need to be addressed by 
adding a honey dilution together with bacterial cultures prior to the biofilm development process, 
as shown by a previous study (Cooper et al., 2011). Moreover, the molecular mechanism through 
which Manuka honey mediates anti-biofilm activity requires further investigation. It is not yet 
well known what the impact of Manuka honey is on the expression of virulence-related genes, 
with an emphasis on the genes involved in biofilm formation, quorum sensing (cell dependent 
bacterial communication) and stress survival.  Hence it is necessary to further explore the impact 
of Manuka honey on the expression of virulence-related genes, in these ESBL producing UTI 
pathogens. 
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Figure 1. Bio film formation process. 1) Reversible attachment; 2) Irreversible 
attachment and formation of exopolysaccharide matrix; 3) Maturation under developed matrix; 









Figure 2. Identification of the ESBL via Double disk synergy. Illustration of the method used - 
K. pneumonia SHV18 as example. 
Table 1. Interpretation of the results from MAST disc Synergy. Strain is regarded as Extended 
Spectrum β Lactamase (ESBL) if zone of inhibition between combination disk with 
clavulanicacid and corresponding antibiotic differs ≥ 5mm, in one or more pairs. Only E. coli 
TEM-3 and K. pneumonia SHV18 were positively recognised as ESBL, showing a difference in 
inhibition zones between combination disk and corresponding antibiotic. CPD – Cefpodoxime; 
CTX – Cefotaxime; CAZ – Ceftazidime; CV - Clavulanic Acid. 
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D52C D62C D64A  
ESBL 
CPD30 CPD CV CTX30 CTX CV CAZ30 CAZ CV 
E. coli TEM3 6 9 9 18 6 15 yes 
E. coli NCTC 12241 22 21 26 26 19 18 no 
K. pneumonia SHV18 13 15 15 22 6 14 yes 
K. pneumonia NCTC 9633 26 24 26 26 20 21 no 
 
Table 2. Well diffusion assay performed on Muller Hilton agar plated to check activity of 50% 
(w/v) of Manuka honey on semi-confluent cultures of control and pathogenic strains. The table 
represent zones of inhibition diameters (mm). 
Strain Well 1 Well 2 Well 3    Average 
E. coli TEM-3 15 14 13 14.0 
E. coli NCTC 12241 (control) 26 26 27 26.3 
K. pneumonia SHV18 11 12 12 11.7 
K. pneumonia NCTC 9633 
(control) 
26 28 27 27.0 
*200µm of honey solution was used per well (8mm diameter). 
Table 3. Minimum Inhibitory Concentration (MIC) established for ESBL strains. Values were 
obtained via Spectroscopic assay for MIC of honey according to (Patton et al., 2006). The 
optical density (OD) of wells prior incubation were subtracted from optical density after 
incubation. Percent of inhibition is equal 1 - (OD test well/OD of corresponding control) x 
100. Positive values indicate inhibition of plank tonic bacteria, whereas negative values 
represent growth of bacteria in the culture. SD was calculated to evaluate distribution, from 
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Table 4 Adherence ability of tested strains before and after treatment with Manuka honey. B 




B A B A 
<0.2  - √  -   
0.2-0.4  -  -  - √ 







Figure 3. 24h bio film formation and reduction in bio film biomass of E. coli TEM-3 after 
treatment with 50% (w/v) of Manuka honey. Optical density of re-solubilised dye remaining on 
bio film was measured at 570nm. Bar chart shows 81% of bio film reduction. An Independent T-
test were performed for control and treated bio films showing significant difference in biomass 







Figure 4. 24h bio film formation and reduction in bio film biomass of K. pneumonia SHV18 
after treatment with 50% (w/v) of Manuka honey. Optical density of re-solubilised dye 
remaining on bio film was measured at 570nm. Bar chart shows 52% of bio film reduction. An 
Independent T-test were performed for control and treated bio films showing significant 
difference in biomass reduction (p value = 0.001). Error bars show deviation form mean values. 
